NOF CORPORATION Q4 FY2025 earnings call

• Overall Financial and Dividend Performance

  • NOF achieved record-high revenue, operating profit, ordinary profit, and net profit for full year FY2025, with total consolidated revenue of 238.3 billion yen (+16.1 billion yen YoY), operating profit of 45.3 billion yen (+3.2 billion yen YoY), ordinary profit of 46.6 billion yen (+1.0 billion yen YoY), and net profit of 36.5 billion yen.
  • Full year annual dividend was increased 7 yen to 45 yen per share, and ROE reached 13.4%, exceeding the 12%+ target for FY2025.
  • A 100 billion yen additional treasury share purchase was announced for FY2024, bringing total FY2024 treasury share purchases to 200 billion yen.

• Long-Term Strategic Positioning

  • NOF has defined its 2030 vision as a group that continuously creates new value via chemistry in three focus areas: Life & Healthcare, Environment & Energy, and Electronics & Information. The 2025 Mid-Term Management Plan (MTMP) is Stage II (Revenue Expansion), with a target operating profit of 46.0 billion yen for FY2025, rising to 600 billion yen by 2030.

• Key Growth Segment Strategies

  • Cosmetic-related business (within Functional Chemicals) operates a closed-loop growth cycle: starting from raw material development, moving to formulation design and ODM products, using market insights to inform new raw material development. The dual raw material/ODM model drives competitive advantage, with high-value hair/skincare/bodycare raw materials and anti-aging/skincare/haircare ODM products both growing strongly; future growth will focus on plant-derived eco-friendly raw materials and high-functionality finished products.
  • DDS pharmaceutical raw materials (within Pharma/Healthcare) saw a temporary 2024 demand lull after strong 2023 growth, but medium-term growth projections are unchanged: more than 5 late-stage pipeline projects are in progress, and the new LS Aichi Plant will start commercial operations in October 2025 to prepare for future demand growth, with capacity utilization expected to rise gradually over the medium term.
  • Defense-related products (within Kayaku Segment) are seeing rapidly growing demand driven by Japan's expanded defense buildup plans. NOF is planning up to 100 billion yen in total capital expenditure to expand propellant manufacturing capacity, with initial investment costs to be recovered from customer first-cost payments; deliveries are scheduled to start in the next mid-term plan period.

• Capital Allocation and Governance Updates

  • Capital expenditure in the 2025 MTMP period is planned to be 3x the level of the prior 2022 MTMP, with spending focused on capacity expansion for growth segments, productivity improvement via automation and digitization, and environmental investments for carbon neutrality by 2050.
  • Total R&D spending for FY2025 is planned at 8.8 billion yen, up from 7.9 billion yen in FY2024. NOF has launched a joint research lab with AIST to develop environmentally harmonized chemical manufacturing processes, and is accelerating R&D efficiency via materials informatics.
  • NOF achieved its 2025 MTMP target of reducing cross-shareholdings to below 15% of net assets, hitting 14.8% as of March 2025 after selling 7 holdings, and will continue to reduce holdings going forward.
  • A new employee shareholding incentive scheme was introduced, granting 20 shares annually to participating employees to align employee and shareholder interests.

1. Functional Chemicals Segment: Full year revenue was 150.9 billion yen, an increase of 17.4 billion yen year-over-year. Operating profit was 29.8 billion yen, an increase of 7.8 billion yen year-over-year. This segment contributed 63.3% of total company revenue. Growth was driven by strong performance in cosmetic-related products and special rust inhibitors, with automotive-related shipments to China performing particularly well, while fatty acid derivatives saw weak shipments of refrigeration lubricant base materials in China.
2. Pharma, Medical and Healthcare Segment: Full year revenue was 48.0 billion yen, a decrease of 6.0 billion yen year-over-year. Operating profit was 15.7 billion yen, a decrease of 4.9 billion yen year-over-year. This segment contributed 20.1% of total company revenue. The decline was due to a temporary slowdown in demand for DDS pharmaceutical formulation raw materials from customer inventory adjustments, and revenue declines from product consolidation in edible processed oils and functional food materials.
3. Chemicals (Kayaku) Segment: Full year revenue was 38.8 billion yen, an increase of 4.6 billion yen year-over-year. Operating profit was 3.1 billion yen, an increase of 0.5 billion yen year-over-year. This segment contributed 16.3% of total company revenue. Growth was driven by strong demand and increased sales for both defense-related products and space-related rocket products.

• Management projects that NOF will update its all-time record high performance again in FY2026 (ending March 2026), projecting revenue of 252.0 billion yen, operating profit of 460 billion yen, ordinary profit of 47.9 billion yen, and net profit of 36.8 billion yen, representing a 0.7 billion yen increase in operating profit year-over-year.
• While fatty acid derivatives in Functional Chemicals and DDS raw materials in Pharma/Healthcare are projected to come in below original 2025 MTMP targets, this is fully offset by upside from cosmetic products/special rust inhibitors in Functional Chemicals and defense products in Kayaku, so the overall FY2025 operating profit guidance matches the original 2025 MTMP target of 46.0 billion yen.
• For individual segments: Functional Chemicals is projected to deliver a 0.4 billion yen operating profit increase (above 2025 MTMP target), Pharma/Healthcare is projected to deliver a 0.3 billion yen operating profit increase (below 2025 MTMP target, but with unchanged medium-term growth outlooks), and Kayaku is projected to deliver a 0.4 billion yen operating profit increase.
• The annual dividend for FY2026 is planned at 48 yen per share, a 3 yen increase year-over-year, with a projected payout ratio of 30.5%. NOF will continue to prioritize stable progressive dividends, with a total shareholder return target of ~50% for the 2025 MTMP period, and will consider opportunistic treasury share purchases in FY2026 to improve capital efficiency.
• Management targets to maintain ROE at the 2024 13.4% level for FY2025, and is considering raising the ROE target when developing the 2028 MTMP.

• Uncertainty around U.S. tariff policy means its potential impact has not been included in the FY2026 earnings guidance, and management will continue to monitor any potential adverse impact on NOF's performance if tariff impacts expand.
• Biotech venture clinical development delays in the U.S. due to slow investment environment recovery are continuing, pushing out the expected acceleration of functional lipid growth for DDS products to the longer term.
• Higher fixed costs from labor expenses, depreciation for new capacity (including the LS Aichi Plant), and expansion spending are projected to offset most of the earnings growth from increased sales in FY2026.

The full Q&A exchange content is not included in the provided transcript snippet, so no key exchanges can be summarized.